During recent years, several new anticoagulants have been introduced to the market. The pharmacokinetic assessments of these drugs have shown few drug and food interactions, predictable dose responses, and rapid onset and offset, thus resulting in simplified management of patients requiring anticoagulant therapy. Furthermore, the risk of major bleeding is one-half that of warfarin. We describe the advantages and potential limitations of the new anticoagulants.